Patents by Inventor Jung Beom Son

Jung Beom Son has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10870647
    Abstract: The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: December 22, 2020
    Assignee: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    Inventors: Hwan Geun Choi, Jung Beom Son, Shinae Kim, Seungyeon Lee, Eunhwa Ko, Joongheui Cho, Seock Yong Kang, So Young Kim, Jin-Hee Park, Yi Kyung Ko, Hee Yoon Ryu, Nam Doo Kim, Hyunkyoung Kim, Younho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Seongho Hong, Sang Hyun Min, Sungwoo Lee, Dong Kyu Choi, Jae Hyun Bae, Eunmi Hong, Tae-Ho Jang, Jaeyoung Song, Sangbum Kim, Suk Kyoon Yoon
  • Publication number: 20200239474
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 30, 2020
    Applicants: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hwan Geun CHOI, Jong Bae PARK, Eunhwa KO, Jung Beom SON, Joong-heui CHO, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Nam Doo KIM, Yunho LEE, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Jae Hyun BAE, Eunmi HONG, Tae-ho JANG, Sang Bum KIM, Seung Hoon LEE, Do-Hyun NAM
  • Publication number: 20200207756
    Abstract: The present invention relates to a pyrrolopyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 2, 2020
    Inventors: Hwan Geun CHOI, Eunhwa KO, Joong-heui CHO, Jung Beom SON, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Hee Yoon RYU, Nam Doo KIM, Sang Bum KIM, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Sungchan CHO, Kyu-Sun LEE, Kweon YU, Miri CHOI, Ja Wook KOO, Hyang-Sook HOE
  • Publication number: 20190315738
    Abstract: The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 17, 2019
    Applicant: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    Inventors: Hwan Geun Choi, Jung Beom Son, Shinae Kim, Seungyeon Lee, Eunhwa Ko, Joongheui Cho, Seock Yong Kang, So Young Kim, Jin-Hee Park, Yi Kyung Ko, Hee Yoon Ryu, Nam Doo Kim, Hyunkyoung Kim, Younho Lee, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Seongho Hong, Sang Hyun Min, Sungwoo Lee, Dong Kyu Choi, Jae Hyun Bae, Eunmi Hong, Tae-ho Jang, Jaeyoung Song, Sangbum Kim, Suk Kyoon Yoon
  • Patent number: 10442796
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 15, 2019
    Assignees: Korea Institute of Science and Technology, Daegu-Gyeongbuk Medical Innovation Foundation
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Publication number: 20190047993
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 14, 2019
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Patent number: 10112954
    Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 30, 2018
    Assignees: HANMI PHARM. CO., LTD., HANMI SCIENCE CO., LTD.
    Inventors: Seung Hyun Jung, Young Hee Jung, Wha Il Choi, Jung Beom Son, Eun Ju Jeon, In Ho Yang, Tae Hun Song, Mi Kyoung Lee, Myoung Sil Ko, Young Gil Ahn, Maeng Sup Kim, Young Jin Ham, Tae Bo Sim, Hwan Geun Choi, Jung Mi Hah, Dong-sik Park, Hwan Kim
  • Patent number: 9156852
    Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: October 13, 2015
    Assignee: HANMI PHARM. CO., LTD
    Inventors: In Hwan Bae, Jung Beom Son, Sang Mi Han, Eun Joo Kwak, Ho Seok Kim, Ji Young Song, Eun Young Byun, Seung Ah Jun, Young Gil Ahn, Kwee Hyun Suh
  • Patent number: 8999973
    Abstract: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 7, 2015
    Assignees: Hanmi Science Co., Ltd, Korea Institute of Science and Technology, Catholic University Industry Academic Cooperation Foundation
    Inventors: Jung Beom Son, Seung Hyun Jung, Wha II Choi, Young Hee Jung, Jae Yul Choi, Ji Yeon Song, Kyu Hang Lee, Jae Chul Lee, Eun Young Kim, Young Gil Ahn, Maeng Sup Kim, Hwan Geun Choi, Tae Bo Sim, Young Jin Ham, Dong-sik Park, Hwan Kim, Dong-Wook Kim
  • Publication number: 20140371219
    Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.
    Type: Application
    Filed: December 27, 2012
    Publication date: December 18, 2014
    Applicant: HANMI PHARM. CO., LTD
    Inventors: In Hwan Bae, Jung Beom Son, Sang Mi Han, Eun Joo Kwak, Ho Seok Kim, Ji Young Song, Eun Young Byun, Seung Ah Jun, Young Gil Ahn, Kwee Hyun Suh
  • Patent number: 8853213
    Abstract: The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: October 7, 2014
    Assignee: Hanmi Pharm. Co., Ltd
    Inventors: Jung Beom Son, Nam Du Kim, Young Kil Chang, Hee Cheol Kim, Ji Sook Kim, Young Hee Jung
  • Patent number: 8754209
    Abstract: Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: June 17, 2014
    Assignees: Korea Institute of Science and Technology, Korea Research Institute of Chemical Technology, Korea Research Institute of Bioscience and Biotechnology
    Inventors: Tae Bo Sim, Jung Beom Son, Hwan Kim, Dong Sik Park, Hwan Geun Choi, Young Jin Ham, Jung Mi Hah, Kyung Ho Yoo, Chang Hyun Oh, So Ha Lee, Jae Du Ha, Sung Yun Cho, Byoung Mog Kwon, Dong Cho Han
  • Publication number: 20130274268
    Abstract: The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.
    Type: Application
    Filed: December 29, 2011
    Publication date: October 17, 2013
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Jung Beom Son, Nam Du Kim, Young Kil Chang, Hee Cheol Kim, Ji Sook Kim, Young Hee Jung
  • Publication number: 20130053370
    Abstract: The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.
    Type: Application
    Filed: January 31, 2011
    Publication date: February 28, 2013
    Applicants: HANMI SCIENCE CO., LTD., CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jung Beom Son, Seung Hyun Jung, Wha ll Choi, Young Hee Jung, Jae Yul Choi, Ji Yeon Song, Kyu Hang Lee, Jae Chul Lee, Eun Young Kim, Young Gil Ahn, Maeng Sup Kim, Hwan Geun Choi, Tae Bo Sim, Young Jin Ham, Dong-sik Park, Hwan Kim, Dong-Wook Kim
  • Publication number: 20120302567
    Abstract: The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 29, 2012
    Applicants: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, HANMI PHARM. CO. LTD.
    Inventors: Seung Hyun Jung, Young Hee Jung, Wha Il Choi, Jung Beom Son, Eun Ju Jeon, In Ho Yang, Tae Hun Song, Mi Kyoung Lee, Myoung Sil Ko, Young Gil Ahn, Maeng Sup Kim, Young Jin Ham, Tae Bo Sim, Hwan Geun Choi, Jung Mi Han, Dong-sik Park, Hwan Kim
  • Publication number: 20120130069
    Abstract: Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.
    Type: Application
    Filed: December 4, 2009
    Publication date: May 24, 2012
    Inventors: Tae Bo Sim, Jung Beom Son, Hwan Kim, Dong Sik Park, Hwan Geun Choi, Young Jin Ham, Jung Mi Hah, Kyung Ho Yoo, Chang Hyun Oh, So Ha Lee, Jae Du Ha, Sung Yun Cho, Byoung Mog Kwon, Dong Cho Han
  • Patent number: RE47451
    Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: June 25, 2019
    Assignee: Hanmi Pharm. Co. Ltd.
    Inventors: In Hwan Bae, Jung Beom Son, Sang Mi Han, Eun Joo Kwak, Ho Seok Kim, Ji Young Song, Eun Young Byun, Seung Ah Jun, Young Gil Ahn, Kwee Hyun Suh